Document is current

Article History

Received: 17 April 2019

Accepted: 10 September 2019

First Online: 18 September 2019

Ethics approval and consent to participate

: The Swiss HCVree Trial was approved by the lead ethic committee in Zurich, Switzerland () under the reference number BASEC 2016–00131 (locally responsible for the University Hospital Zurich and Klinik im Park). Local ethics committee Bern (University Hospital Bern), Northwest/Central (EKNZ) (University Hospital Basel), Geneva (University Hospital of Geneva), Ostschweiz (EKOS) (Cantonal Hospital St. Gallen), Ticino (Regional Hospital Lugano), and Vaud (University Hospital Center Lausanne) approved as well. All participants provided written informed consent prior to participation.

: Not Applicable.

: PKH received consultancy fees from Sigma-Tau, Norgine, AbbVie and grants from ViiV, Merck, and Janssen; all outside the submitted work.SE has no conflict of interest.MB has no conflict of interest.KF has no conflict of interest.NH has no conflict of interest.AJS has no conflict of interest.AK reports grant from Merck outside submitted work.CN has no conflict of interest.BH has no conflict of interest.MSt reports board memberships with AbbVie, Gilead, and MSD.CB reports fees from AbbVie, MSD, and Gilead, outside the submitted work.JD has no conflict of interest.PS received travel grants from Merck, outside submitted work.MF has no conflict of interest.MR reports grants from MSD and ViiV outside submitted work.DLB received consultancy fees from Merck, Gilead, and ViiV.JF is a member of the Federal Commission for Sexual Health. He received research, educational and travel grants from Janssen, Merck and ViiV Healthcare.DN reports grants from Merck, Janssen, and ViiV outside submitted work.